GALAPAGOS NV |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.88 EUR | 0.00% |
|
0.00% | 0.00% |
| 05-31 | Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment | MT |
| 05-31 | Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 59.28B | - | |||||
| 40.94B | ||||||
| 40.17B | ||||||
| 28.69B | ||||||
| 26.63B |
